Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Type:
Application
Filed:
December 26, 2017
Publication date:
July 5, 2018
Applicants:
Orphazyme ApS, Orphazyme ApS
Inventors:
Thomas Kirkegaard Jensen, Marja H. Jaattela
Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
February 6, 2018
Assignee:
Orphazyme ApS
Inventors:
Thomas Kirkegaard Jensen, Marja H. Jaattela
Abstract: The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.
Type:
Grant
Filed:
November 22, 2011
Date of Patent:
May 30, 2017
Assignee:
Orphazyme ApS
Inventors:
Thomas Kirkegaard Jensen, Anders Mørkeberg Hinsby
Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Type:
Grant
Filed:
August 19, 2013
Date of Patent:
March 22, 2016
Assignee:
Orphazyme Aps
Inventors:
Thomas Kirkegaard Jensen, Marja H. Jaattela
Abstract: The invention relates to the use of a chemical substance selected from the group consisting of N-?2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
Type:
Grant
Filed:
September 12, 2011
Date of Patent:
February 24, 2015
Assignee:
Orphazyme ApS
Inventors:
Linda Greensmith, Geoffrey Burnstock, Rudolf Urbanics
Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Type:
Application
Filed:
August 19, 2013
Publication date:
February 20, 2014
Applicant:
ORPHAZYME APS
Inventors:
Thomas Kirkegaard Jensen, Marja H. Jaattela
Abstract: The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.
Type:
Application
Filed:
November 22, 2011
Publication date:
September 5, 2013
Applicant:
ORPHAZYME APS
Inventors:
Thomas Kirkegaard Jensen, Anders Morkeberg Hinsby